Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LPL | P06858 | 4/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.36 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | F12 | P00748 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14904906 | 0.82 | ENPP2 (0.44) | KDM4EENPP2PLGF12F11 | |
| SCHEMBL13921939 | 0.80 | F11 (0.41) | CYP1A2POLBKDM4ELMNACYP3A4 | |
| SCHEMBL17304227 | 0.79 | ENPP2 (0.38) | CYP1A2POLBKDM4EENPP2NOS3 | |
| SCHEMBL2562348 | 0.78 | KDM4E (0.36) | CYP1A2POLBLPLLIPGKDM4E | |
| SCHEMBL15331651 | 0.77 | ENPP2 (0.46) | LPLLIPGKDM4ELMNACYP3A4 | |
| SCHEMBL939335 | 0.74 | ENPP2 (0.41) | LPLLIPGKDM4ELMNACYP3A4 | |
| SCHEMBL2562909 | 0.74 | NOS3 (0.39) | CYP1A2LPLLIPGKDM4ELMNA | |
| SCHEMBL29951987 | 0.74 | LPL (0.43) | LPLLIPGENPP2NOS3NOS2 | |
| SCHEMBL29956753 | 0.73 | ACACB (0.37) | LPLLIPGENPP2PLGF12 | |
| SCHEMBL2066753 | 0.73 | ACACB (0.37) | LPLLIPGENPP2PLGF12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360131-A1 | BIARYL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-10-31 | — | — | US | disclosed |
| US-12065437-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-20 | — | — | US | disclosed |
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-114450274-A | Indazoles and azaindazoles as LRRK2 inhibitors | 伊斯凯普生物公司 | 2022-05-06 | — | — | CN | disclosed |
| US-20210277001-A1 | BIARYL KINASE INHIBITORS | Cosmic Pet LLC | 2021-09-09 | — | — | US | disclosed |
| EP-3807269-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | F. Hoffmann-La Roche AG (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-10981910-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-20 | — | — | US | disclosed |
| US-10968215-B2 | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
| WO-2012131588-A1 | 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012101184-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | WO | disclosed |
| US-8222424-B2 | Arylsulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| EP-2421846-A1 | 5-ALKYNYL-PYRIDINES | Boehringer Ingelheim International GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
| US-20110098275-A1 | 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | US | disclosed |
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| EP-2268612-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010122069-A1 | 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2009118292-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| US-7485725-B1 | Pyridine-4-boronic acids 2-substituted with a halogen atom or an organometallating group, e.g., 2-aminomethyl-; used in pharmacological discovery research applications | FRONTIER SCIENTIFIC, INC. (US) | 2009-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | GABRA5, GABRA2, GABRB2 | CYP1A2 407/4885POLB 3851/4885LPL 4456/4885 |
| US-10981910-B2 | Biaryl kinase inhibitors | AAK1, NCK1, MARCKS | CYP1A2 4345/4885POLB 3534/4885LPL 2118/4885 |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB2, GABRB1 | CYP1A2 877/4885POLB 4267/4885LPL 4765/4885 |
| US-10968215-B2 | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof | EZH2, IKZF2, SUZ12 | CYP1A2 3428/4885POLB 3003/4885LPL 4875/4885 |
| US-20110014186-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | MMP11, MMP10, MMP9 | CYP1A2 123/4885POLB 1865/4885LPL 539/4885 |
| US-20210277001-A1 | BIARYL KINASE INHIBITORS | AAK1, NCK1, MARCKS | CYP1A2 4345/4885POLB 3534/4885LPL 2118/4885 |
| US-12065437-B2 | Biaryl kinase inhibitors | AAK1, NCK1, MARCKS | CYP1A2 4345/4885POLB 3534/4885LPL 2118/4885 |
| US-20110098275-A1 | 5-ALKYNYL-PYRIDINES | MKI67, KIT, CCNA1 | CYP1A2 358/4885POLB 3602/4885LPL 4150/4885 |
| US-20240360131-A1 | BIARYL KINASE INHIBITORS | AAK1, NCK1, MARCKS | CYP1A2 4345/4885POLB 3534/4885LPL 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.